References
1. Siegler JE, Martin-Schild S. Early neurological deterioration (END) after stroke: the END depends on the definition. Int J Stroke 2011;6:211-212.
2. Roquer J, Rodriguez-Campello A, Gomis M, et al. Acute stroke unit care and early neurological deterioration in ischemic stroke. J Neurol 2008;255:1012-1017.
3. Kwan J, Hand P. Early neurological deterioration in acute stroke: clinical characteristics and impact on outcome. QJM 2006;99:625-633.
4. Adams HP, Jr Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126-131.
5. Siegler JE, Boehme AK, Kumar AD, et al. Identification of modifiable and nonmodifiable risk factors for neurologic deterioration after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e207-e213.
6. Weimar C, Mieck T, Buchthal J, et al. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 2005;62:393-397.
7. Castillo J, Leira R, Garcia MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:520-526.
8. Ogata T, Yasaka M, Wakugawa Y, et al. Predisposing factors for acute deterioration of minor ischemic stroke. J Neurol Sci 2009;287:147-150.
9. Seet RC, Zhang Y, Wijdicks EF, et al. Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol 2011;68:1454-1458.
10. Audebert HJ, Rott MM, Eck T, et al. Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke 2004;35:2128-2133.
11. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
12. IST-3 Collaborative Group., Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial <IST-3]): a randomised controlled trial. Lancet 2012;379:2352-2363.
13. Hemmen TM, Ernstrom K, Raman R. Two-hour improvement of patients in the National Institute of Neurological Disorders and Stroke trials and prediction of final outcome. Stroke 2011;42:3163-3167.
14. Yeo LL, Paliwal P, Teoh HL, et al. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e590-e596.
15. Muresan IP, Favrole P, Levy P, et al. Very early neurologic improvement after intravenous thrombolysis. Arch Neurol 2010;67:1323-1328.
16. Siegler JE, Boehme AK, Dorsey AM, et al. A comprehensive stroke center patient registry: advantages, limitations, and lessons learned. Med Stud Res J 2013;2:21-29.
17. Adams HP, Jr Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
18. Siegler JE, Martin-Schild S. Daily National Institutes of Health Stroke Scale examinations at stroke centers: why not do them? Int J Stroke 2015;10:140-142.
19. Siegler JE, Boehme AK, Kumar AD, et al. What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke? J Stroke Cerebrovasc Dis 2013;22:675-682.
20. Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001;32:661-668.
21. Toyoda K, Fujimoto S, Kamouchi M, et al. Acute blood pressure levels and neurological deterioration in different subtypes of ischemic stroke. Stroke 2009;40:2585-2588.
22. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
23. Alexandrov AV, Felberg RA, Demchuk AM, et al. Deterioration following spontaneous improvement: sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke 2000;31:915-919.
24. Siegler JE, Boehme AK, Albright KC, et al. A proposal for the classification of etiologies of neurologic deterioration after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e549-e556.
25. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
26. Machumpurath B, Davis SM, Yan B. Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome. Cerebrovasc Dis 2011;31:278-283.
27. Felberg RA, Okon NJ, El-Mitwalli A, et al. Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke 2002;33:1301-1307.
28. Blinzler C, Breuer L, Huttner HB, et al. Characteristics and outcome of patients with early complete neurological recovery after thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2011;31:185-190.
29. Saposnik G, Young B, Silver B, et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA 2004;292:1839-1844.
30. Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007;38:2275-2278.
31. Nakajima M, Hirano T, Naritomi H, et al. Symptom progression or fluctuation in transient ischemic attack patients predicts subsequent stroke. Cerebrovasc Dis 2010;29:221-227.
32. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
33. Nacu A, Bringeland GH, Khanevski A, et al. Early neurological worsening in acute ischaemic stroke patients. Acta Neurol Scand 2016;133:25-29.
34. Hwang YH, Seo JG, Lee HW, et al. Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke. Cerebrovasc Dis 2008;26:355-359.
35. Siegler JE, Samai A, Semmes E, et al. Early neurologic deterioration after stroke depends on vascular territory and stroke etiology. J Stroke 2016;18:203-210.
36. Yamamoto H, Bogousslavsky J, van Melle G. Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998;55:481-486.
37. Davalos A, Toni D, Iweins F, et al. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke 1999;30:2631-2636.
38. Mori M, Naganuma M, Okada Y, et al. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry. Cerebrovasc Dis 2012;34:140-146.
39. Siegler JE, Albright KC, George AJ, et al. Time to neurological deterioration in ischemic stroke. Med Stud Res J 2016. In press.
40. Siegler JE. The utility of quantifiable neurologic assessments after stroke: in response to Marsh et al,"The NIH Stroke Scale has limited utility in accurate daily monitoring of neurologic status.". Neurohospitalist 2016;6:95-96.
41. Liao Y, Greenlund KJ, Croft JB, et al. Factors explaining excess stroke prevalence in the US Stroke Belt. Stroke 2009;40:3336-3341.
42. Kleindorfer D, Lindsell CJ, Brass L, et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928.
43. Bambauer KZ, Johnston SC, Bambauer DE, et al. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006;63:661-664.